Recent Research Analysts’ Ratings Updates for Korro Bio (KRRO)

Korro Bio (NASDAQ: KRRO) has recently received a number of price target changes and ratings updates:

• 3/28/2024 – Korro Bio had its price target raised by analysts at HC Wainwright from $100.00 to $115.00. They now have a “buy” rating on the stock.
• 3/27/2024 – Korro Bio had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $180.00 price target on the stock.
• 3/27/2024 – Korro Bio had its price target raised by analysts at Royal Bank of Canada from $70.00 to $90.00. They now have an “outperform” rating on the stock.
• 3/26/2024 – Korro Bio had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $120.00 price target on the stock.
• 2/27/2024 – Korro Bio is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $120.00 price target on the stock.

Korro Bio Stock Down 7.9 %

NASDAQ KRRO opened at $82.65 on Wednesday. The firm has a market capitalization of $61.16 million, a P/E ratio of -0.87 and a beta of 2.18. Korro Bio, Inc. has a twelve month low of $9.15 and a twelve month high of $97.91. The firm has a fifty day moving average of $58.23.

Institutional Trading of Korro Bio

A number of large investors have recently bought and sold shares of KRRO. North Star Investment Management Corp. bought a new position in shares of Korro Bio during the 4th quarter worth about $48,000. Tower Research Capital LLC TRC bought a new position in shares of Korro Bio during the 4th quarter worth about $190,000. Northern Trust Corp bought a new position in shares of Korro Bio during the 4th quarter worth about $504,000. Verition Fund Management LLC bought a new position in shares of Korro Bio during the 4th quarter worth about $2,784,000. Finally, Monashee Investment Management LLC bought a new position in shares of Korro Bio during the 4th quarter worth about $4,352,000. 13.18% of the stock is currently owned by institutional investors and hedge funds.

Korro Bio, Inc, a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc is based in Cambridge, Massachusetts.